Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Washington, District of Columbia 20007


- Multi-Center - Randomized - Open-Label Study of single agent IMO-2055 - Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

Study summary:

This is a study of 2 dose levels (0.16 or 0.64 mg/kg) of IMO-2055 administered by weekly subcutaneous (SC) injections in two patient populations, treatment naïve or previously treated patients. Each dose group (treatment naive or previously treated) will be randomized to receive one of the 2 doses being studied.


Inclusion Criteria: - Histologically confirmed stage IV clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable. - At least one measurable lesion - Adequate organ function - Any prior treatment of renal cell cancer was concluded at least 4 weeks prior. - If female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug. Exclusion Criteria: - Known untreated central nervous system (CNS) metastasis - Pre-existing autoimmune or antibody-mediated diseases - Other significant medical disease.



Primary Contact:

Study Director
Alice Bexon, MD
Idera Pharmaceuticals

Backup Contact:


Location Contact:

Washington, District of Columbia 20007
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.